Article Search

Full publication of the ESOPEC trial which was presented at ASCO-2024. Essentially perioperative FLOT beat preoperative carbo/taxol/XRT. One call out is that this study began before the era of using postoperative IO therapy for those with residual disease at the time of esophagectomy after neoadjuvant chemoradiation. Also, I would suggest that for bulky or node+ tumors, it may be worthwhile to consider a TNT-type approach as only ~50% of patients complete the four postoperative cycles of FLOT.

Her2-low is here to stay.  Expect further studies on Enhertu and Trodelvy on gastroesophageal Her-2 low patients.  Response rates were modest however, so temper expectations as single agent therapy.  I look forward to trials on future combination therapy.